Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

While multiple myeloma (MM) treatment with proteasome inhibitors and other agents yields encouraging results, primary and secondary resistance remains an emerging problem. An important factor in such treatment resistance is the overexpression of several proteins. The present study comprehensively ev...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paweł Robak, Janusz Szemraj, Damian Mikulski, Izabela Drozdz, Karolina Juszczak, Dariusz Jarych, Małgorzata Misiewicz, Kacper Kościelny, Wojciech Fendler, Tadeusz Robak
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
bortezomib
cMAF
MAFb
multiple myeloma
POMP
prognosis
Medicine
R
Acceso en línea:https://doaj.org/article/3c8e56eba9894fddbdb44071e012f57c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares